drugset / Trial / NCT01888744
Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
RandomizedParallel-groupSingle-blindTreatment
Summary
The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).
Timeline
- Start
- 2010-09
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cetrorelix | Other / unclassified | — | — |
| Comparator | Decapeptyl | Unknown | 0.1 mg | Subcutaneous |
| Comparator | Ganirelix | Protein / enzyme biologic | 0.25 mg | Subcutaneous |
| Comparator | buserelin | Unknown | 600 ug | Intranasal |
| Comparator | Menopur | Protein / enzyme biologic | 225 iu | Subcutaneous |
| Comparator | Progesterone | Other / unclassified | — | Other |
| Comparator | human chorionic gonadotropin | Protein / enzyme biologic | — | — |